MR blockade in patients with chronic renal disease - Not the more the merrier, but the earlier the better [11]

Nephrology Dialysis Transplantation

Volumn 21, Issue 11, 2006, Pages 3343-3344

  Lepenies, Julia ^a   Quinkler, Marcus ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EPLERENONE; INTERLEUKIN 6; MINERALOCORTICOID RECEPTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; SPIRONOLACTONE; TRANSFORMING GROWTH FACTOR BETA1;

ALBUMINURIA; CARDIOMYOPATHY; CHRONIC KIDNEY DISEASE; DOSE RESPONSE; DRUG EFFICACY; ERECTILE DYSFUNCTION; GYNECOMASTIA; HUMAN; HYPERKALEMIA; HYPERTENSION; LETTER; LIBIDO DISORDER; MASTALGIA; MENSTRUATION DISORDER; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOGENESIS; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BLOCKING; RENAL PROTECTION; RENAL REPLACEMENT THERAPY;

ALDOSTERONE ANTAGONISTS; ANIMALS; DRUG ADMINISTRATION SCHEDULE; HUMANS; KIDNEY FAILURE, CHRONIC; RATS; RECEPTORS, MINERALOCORTICOID; SPIRONOLACTONE;

EID: 33749995791     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfl371     Document Type: Letter

References (15)

1. Covic A, Gusbeth-Tatomir P, Goldsmith DJA. Is it time for spironolactone therapy in dialysis patients? Nephrol Dial Transplant 2006; 21: 854-858
2. Jeunemaitre X, Chatellier G, Kreft-Jais C et al. Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol 1987; 60: 820-825
3. Stowasser M. Primary aldosteronism: Revival of a syndrome. J Hypertens 2001; 19: 363-366
4. Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003; 16: 925-930
5. Blasi ER, Rocha R, Rudolph AE, Blomme EA, Polly ML, McMahon EG. Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int 2003; 63: 1791-1800
6. Rocha R, Stier CT,Jr, Kifor I et al. Aldosterone: A mediator of myocardial necrosis and renal arteriopathy. Endocrinology 2000; 141: 3871-3878
7. Rocha R, Chander PN, Zuckerman A, Stier CT,Jr. Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension 1999; 33: 232-237
8. Chrysostomou A, Becker G. Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease. N Engl J Med 2001; 345: 925-926
9. Epstein M. Aldosterone receptor blockade and the role of eplerenone: evolving perspectives. Nephrol Dial Transplant 2003; 18: 1984-1992
10. Sato A, Hayashi K, Naruse M, Saruta T. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003; 41: 64-68
11. Bianchi S, Bigazzi R, Campese VM. Antagonists of aldosterone and proteinuria in patients with CKD: An uncontrolled pilot study. Am J Kidney Dis 2005; 46: 45-51
12. Quinkler M, Zehnder D, Eardley KS et al. Increased expression of mineralocorticoid effector mechanisms in kidney biopsies of patients with heavy proteinuria. Circulation 2005; 112: 1435-1443
13. McLaughlin N, Gehr TW, Sica DA. Aldosterone-receptor antagonism and end-stage renal disease. Curr Hypertens Rep 2004; 6: 327-330
14. Barnes BJ, Howard PA. Eplerenone: A selective aldosterone receptor antagonist for patients with heart failure. Ann Pharmacother 2005; 39: 68-76
15. Levy DG, Rocha R, Funder JW. Distinguishing the antihypertensive and electrolyte effects of eplerenone. J Clin Endocrinol Metab 2004; 89: 2736-2740